OTLK MEXC RealStocks
Own real OTLK shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 22:05:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Outlook Therapeutics, Inc. (OTLK) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.44, with a market capitalization of $112.13M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.16 to $2.54. This page covers its latest market performance, valuation, price trends and company information.
$112.13M | |
$0.48 | |
$0.48 | |
$0.44 | |
$0.48 | |
2.36M | |
8.42M | |
-- | |
$2.54 | |
$0.16 | |
-- | |
-- |
Outlook Therapeutics, Inc. (OTLK) is trading at $0.45 in after-hours trading as of 2026-11-12 22:02:00, up 2.72% ($0.01) from the regular-session close of $0.44.
After-hours trading shows how investors are pricing OTLK after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Outlook Therapeutics, Inc. (OTLK) moved from $0.46 to $0.44, representing a decline of 4.13% ($0.02).
The stock traded between $0.41 and $0.50 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 2.34 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 11.8%
OTLK is currently trading at $0.44, placing it 11.8% of the way from its 52-week low of $0.16 to its 52-week high of $2.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Outlook Therapeutics, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Outlook Therapeutics, Inc. (OTLK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to OTLK, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between OTLK shares and USD.
OTLK Shares to USD
1.00 OTLK shares = 0.441 USD
Calculations are estimates based on the latest available price and are for reference only.